Hypersensitivity reactions to Proton Pump Inhibitors. An EAACI Position
Proton pump inhibitors (PPIs) are invaluable therapeutic options in a
variety of dyspeptic diseases. In addition to their well-known risk
profile, PPI consumption is related to food and environmental allergies,
dysbiosis, osteoporosis, as well as immediate and delayed
hypersensitivity reactions (HSRs). The latter, although a rare event,
around 1-3%, due to the extraordinarily high rate of prescription and
consumption of PPIs are related to a substantial risk. In this Position
Paper, we provide clinicians with practical evidence-based
recommendations for the diagnosis and management of HSRs to PPIs.
Furthermore, the unmet needs proposed in the document aim to stimulate
more in-depth investigations in the topic.